{"DataElement":{"publicId":"5473447","version":"1","preferredName":"Person Laboratory Procedure Alkaline Phosphatase Measurement Disease or Disorder Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A response to determine eligibility for clinical trial participation for questions related to the measurement of alkaline phosphatase present in a sample with any abnormal medical condition of the patient.","longName":"ALP_DZ_IND","context":"Theradex","contextVersion":"1","DataElementConcept":{"publicId":"5473444","version":"1","preferredName":"Person Laboratory Procedure Alkaline Phosphatase Measurement Disease or Disorder Clinical Trial Eligibility Criteria","preferredDefinition":"A human being._Any procedure that involves testing or manipulating a sample of blood, urine, or other body substance in a laboratory setting._A quantitative measurement of alkaline phosphatase present in a sample._Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function._Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria.","longName":"5473441v1.0:5473442v1.0","context":"Theradex","contextVersion":"1","ObjectClass":{"publicId":"5473441","version":"1","preferredName":"Person Laboratory Procedure","preferredDefinition":"A human being.:Any procedure that involves testing or manipulating a sample of blood, urine, or other body substance in a laboratory setting.","longName":"C25190:C25294","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Person","conceptCode":"C25190","definition":"A human being.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Laboratory Procedure","conceptCode":"C25294","definition":"Any procedure that involves testing or manipulating a sample of blood, urine, or other body substance in a laboratory setting.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3CF3DD88-0EFC-32C2-E053-F662850A64EC","latestVersionIndicator":"Yes","beginDate":"2016-09-20","endDate":null,"createdBy":"TAYLORT","dateCreated":"2016-09-20","modifiedBy":"ONEDATA","dateModified":"2016-09-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"5473442","version":"1","preferredName":"Alkaline Phosphatase Measurement Disease or Disorder Clinical Trial Eligibility Criteria","preferredDefinition":"A quantitative measurement of alkaline phosphatase present in a sample.:Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function.:Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria.","longName":"C64432:C2991:C16112","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Alkaline Phosphatase Measurement","conceptCode":"C64432","definition":"A quantitative measurement of alkaline phosphatase present in a sample.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Disease or Disorder","conceptCode":"C2991","definition":"Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Clinical Trial Eligibility Criteria","conceptCode":"C16112","definition":"Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3CF3DD88-0F0E-32C2-E053-F662850A64EC","latestVersionIndicator":"Yes","beginDate":"2016-09-20","endDate":null,"createdBy":"TAYLORT","dateCreated":"2016-09-20","modifiedBy":"ONEDATA","dateModified":"2016-09-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008525","version":"1","preferredName":"Eligibility","preferredDefinition":"trial-specific criteria that a patient must meet to be enrolled.","longName":"ELIG","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1EC3968-9F25-305A-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-16","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-16","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"3CF3DD88-0F1F-32C2-E053-F662850A64EC","latestVersionIndicator":"Yes","beginDate":"2016-09-20","endDate":null,"createdBy":"TAYLORT","dateCreated":"2016-09-20","modifiedBy":"TAYLORT","dateModified":"2016-09-26","changeDescription":"9/26/16 tt, approved/released.\r\n9/20/16 tt, created for 10020.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3298541","version":"1","preferredName":"Yes No Not Applicable Code Indicator","preferredDefinition":"Indicator to represent a response of Yes, No, or Not Applicable._The affirmative response to a question or activity._The non-affirmative response to a question._Determination that a value is not relevant in the current context._A system of numbered categories for representation of data.","longName":"YES_NO_NA_CD_IND","context":"CCR","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":"1","maxLength":"1","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"X","valueDescription":"Not applicable","ValueMeaning":{"publicId":"2581003","version":"1","preferredName":"Not applicable","longName":"2581003v1.00","preferredDefinition":"Determination of a value is not relevant in the current context.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Not Applicable","conceptCode":"C48660","definition":"Determination of a value is not relevant in the current context.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0978-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-12-31","endDate":null,"createdBy":"SBREXT","dateCreated":"2003-12-31","modifiedBy":"CLOHNES","dateModified":"2023-11-09","changeDescription":null,"administrativeNotes":"2023.3.6 Added Alt VM-COG. ak","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B04AC04D-C223-0627-E040-BB89AD432C31","beginDate":"2002-02-11","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"ONEDATA","dateModified":"2011-10-27","deletedIndicator":"No"},{"value":"N","valueDescription":"No","ValueMeaning":{"publicId":"2559515","version":"1","preferredName":"No","longName":"2559515","preferredDefinition":"The non-affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B588-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"GDEEN","dateModified":"2024-01-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B04AC04D-C22D-0627-E040-BB89AD432C31","beginDate":"2002-08-22","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"ONEDATA","dateModified":"2011-10-27","deletedIndicator":"No"},{"value":"Y","valueDescription":"Yes","ValueMeaning":{"publicId":"2560453","version":"1","preferredName":"Yes","longName":"2560453","preferredDefinition":"The affirmative response to a question or activity.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes","conceptCode":"C49488","definition":"The affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B932-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"CLOHNES","dateModified":"2023-09-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B04AC04D-C237-0627-E040-BB89AD432C31","beginDate":"2002-08-22","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"ONEDATA","dateModified":"2011-10-27","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008551","version":"1","preferredName":"Assessments","preferredDefinition":"evaluations of the patient and the patient's disease.","longName":"ASSESS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22DA727-6718-5A2D-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"3298540","version":"1","preferredName":"Yes No Not Applicable Code Indicator","preferredDefinition":"The affirmative response to a question or activity.:The non-affirmative response to a question.:Determination that a value is not relevant in the current context.:A system of numbered categories for representation of data.:An event, entity or condition that typically characterizes a prescribed environment or situation and determines or aids in determining whether certain stated circumstances exist or criteria are satisfied.","longName":"3298540v1.0","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes","conceptCode":"C49488","definition":"The affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Not Applicable","conceptCode":"C48660","definition":"Determination of a value is not relevant in the current context.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Code","conceptCode":"C25162","definition":"A symbol or combination of symbols which is assigned to the members of a collection.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Indicator","conceptCode":"C25180","definition":"An event, entity or condition that typically characterizes a prescribed environment or situation and determines or aids in determining whether certain stated circumstances exist or criteria are satisfied.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B04AC04D-C1F2-0627-E040-BB89AD432C31","latestVersionIndicator":"Yes","beginDate":"2011-10-27","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"ONEDATA","dateModified":"2011-10-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"CTMS:Clinical Trials Monitoring Service","workflowStatus":"RELEASED","registrationStatus":"Application","id":"B04AC04D-C203-0627-E040-BB89AD432C31","latestVersionIndicator":"Yes","beginDate":"2011-10-27","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"MAESKEB","dateModified":"2016-01-20","changeDescription":"Created to support Theradex design of CRFs for NCI CCR trials","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"3876352","version":"1","longName":"Inclusion Criteria","context":"Theradex","ClassificationSchemeItems":[{"publicId":"3876425","version":"1","longName":"Laboratory Data (including serologic/viral status)","context":"Theradex"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"Is pre-study alkaline phospha","type":"Preferred Question Text","description":"Is pre-study alkaline phosphatase less than or equal to 2.5 x upper limit of normal or less than or equal to 5 x upper limit of normal if liver involvement or bone metastases?","url":null,"context":"Theradex"},{"name":"Theradex - 1","type":"Alternate Question Text","description":"Is pre-study alkaline phosphatase less than or equal to 2.5 x upper limit of normal or less than or equal to 5 x upper limit of normal if documented liver involvement or bone metastases?","url":null,"context":"Theradex"},{"name":"Theradex - 2","type":"Alternate Question Text","description":"Is pre-study alkaline phosphatase less than or equal to 2.5 x upper limit of normal?","url":null,"context":"Theradex"},{"name":"Theradex - 3","type":"Alternate Question Text","description":"Is pre-study alkaline phosphatase less than or equal to 2 x upper limit of normal or less than or equal to 5 x upper limit of normal for patients with documented liver involvement or bone metastases?","url":null,"context":"Theradex"},{"name":"Theradex - 4","type":"Alternate Question Text","description":"Is pre-study alkaline phosphatase less than 2.0 x upper limit of normal (or less than 3.0 x upper limit of normal if liver or bone disease is present)?","url":null,"context":"Theradex"},{"name":"Theradex - 5","type":"Alternate Question Text","description":"Is pre-study alkaline phosphatase less than 2.0 x upper limit of normal (if liver or bone metastases are present, less than 3.0 x upper limit of normal)?","url":null,"context":"Theradex"},{"name":"Theradex - 6","type":"Alternate Question Text","description":"Is pre-study alkaline phosphatase less than or equal to 2.5 x upper limit of normal (or less than or equal to 5 x upper limit of normal for patients with documented liver involvement or bone metastases)?","url":null,"context":"Theradex"},{"name":"Theradex - 7","type":"Alternate Question Text","description":"Is pre-study alkaline phosphatase less than or equal to 3.0 x institutional upper limit of normal or less than or equal to 5 x upper limit of normal if documented bone metastases?","url":null,"context":"Theradex"},{"name":"Theradex - 8","type":"Alternate Question Text","description":"Is pre-study alkaline phosphatase less than 2.0 x institutional upper limit of normal (or less than 3.0 x upper limit of normal if liver or bone metastases are present)?","url":null,"context":"Theradex"},{"name":"Theradex - 9","type":"Alternate Question Text","description":"Is alkaline phosphatase less than or equal to 3 x upper limit of normal?","url":null,"context":"Theradex"},{"name":"Theradex - 10","type":"Alternate Question Text","description":"Is pre-study alkaline phosphatase less than or equal to 3 x institutional upper limit of normal?","url":null,"context":"Theradex"},{"name":"Theradex - 11","type":"Alternate Question Text","description":"Is pre-study alkaline phosphatase less than or equal to 2.5 x institutional ULN (or less than or equal to 5 x upper limit of reference range if considered to be related to liver or bone metastases by the PI)?","url":null,"context":"Theradex"},{"name":"Theradex - 12","type":"Alternate Question Text","description":"Is pre-study alkaline phosphatase less than or equal to 2 x institutional upper limit of normal?","url":null,"context":"Theradex"},{"name":"Theradex - 13","type":"Alternate Question Text","description":"Is pre-study alkaline phosphatase less than or equal to 2.5 x upper limit of normal (or less than or equal to 5 x upper limit of normal for patients with documented liver involvement or bone metastases) within 14 days prior to study registration?","url":null,"context":"Theradex"}],"origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"3CF3DD88-0F3C-32C2-E053-F662850A64EC","latestVersionIndicator":"Yes","beginDate":"2016-09-20","endDate":null,"createdBy":"TAYLORT","dateCreated":"2016-09-20","modifiedBy":"KUMMEROA","dateModified":"2023-06-23","changeDescription":"9/26/16 tt, approved/released. 9/20/16 tt, created for 10020.","administrativeNotes":"2023.6.23 Special character corrected per ticket request CADSR0002546. ak","unresolvedIssues":null,"deletedIndicator":"No"}}